As the U.S. stock market navigates a period of volatility, with major indices like the Nasdaq retreating from record highs amid anticipation of key economic data releases, investors are closely watching for signs that could influence future monetary policy decisions. In this climate, high-growth tech stocks in the United States remain a focal point for many investors seeking opportunities in sectors poised to benefit from technological advancements and innovation.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating ACADIA Pharmaceuticals 10.87% 25.66% ★★★★★☆ ADMA Biologics 20.61% 23.25% ★★★★★☆ Palantir Technologies 25.38% 32.02% ★★★★★★ Circle Internet Group 30.80% 60.66% ★★★★★★ Workday 11.38% 29.97% ★★★★★☆ Mereo BioPharma Group 51.11% 57.42% ★★★★★★ OS Therapies 38.35% 16.51% ★★★★★☆ Vanda Pharmaceuticals 22.66% 57.41% ★★★★★☆ Gorilla Technology Group 27.85% 105.48% ★★★★★☆ Aldeyra Therapeutics 49.14% 72.47% ★★★★★☆

Click here to see the full list of 66 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Protagonist Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide therapeutics for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases, with a market cap of $3.18 billion.

Operations: Protagonist Therapeutics generates revenue primarily from its biotechnology segment, specifically focusing on startups, amounting to $209.18 million. The company's efforts are concentrated on developing peptide therapeutics for specific medical conditions.

Protagonist Therapeutics, despite a challenging year with a net loss widening to $46.43 million from a prior net income of $176.72 million, continues to invest in groundbreaking research, particularly in the treatment of polycythemia vera as demonstrated by their successful Phase 3 VERIFY study. This focus on specialized biotech solutions underscores its potential in an industry where innovation directly correlates with market success. The company's significant R&D investments are aimed at pioneering treatments that address unmet medical needs, indicating a strategic push towards securing a strong position within the biotech sector. While recent financial figures show volatility, Protagonist’s aggressive growth strategy in R&D could set them apart if their pipeline products achieve commercial success.

Click here to discover the nuances of Protagonist Therapeutics with our detailed analytical health report. Assess Protagonist Therapeutics' past performance with our detailed historical performance reports.

Story Continues

PTGX Revenue and Expenses Breakdown as at Aug 2025

Palantir Technologies

Simply Wall St Growth Rating: ★★★★★★

Overview: Palantir Technologies Inc. develops software platforms for intelligence and counterterrorism operations globally, with a market cap of $443.53 billion.

Operations: The company generates revenue primarily through its two main segments: Commercial, contributing $1.54 billion, and Government, accounting for $1.90 billion.

Palantir Technologies, a leader in data integration and analytics, has recently raised its full-year revenue guidance to $4.15 billion, marking a substantial 45% year-over-year growth. This adjustment reflects robust U.S. commercial revenue projections, anticipated to surpass $1.3 billion—an 85% increase—demonstrating strong market demand and strategic positioning within the tech sector. In alignment with this growth trajectory, Palantir's commitment to innovation is evident in its R&D investments which have been pivotal in developing advanced AI-driven platforms for diverse federal and commercial applications. These strategic moves not only enhance Palantir’s service offerings but also solidify its role in shaping future tech landscapes by addressing complex data challenges across various industries.

Take a closer look at Palantir Technologies' potential here in our health report. Gain insights into Palantir Technologies' past trends and performance with our Past report.PLTR Earnings and Revenue Growth as at Aug 2025

ServiceNow

Simply Wall St Growth Rating: ★★★★★☆

Overview: ServiceNow, Inc. offers cloud-based solutions for digital workflows across various regions globally and has a market capitalization of $181.06 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $12.06 billion.

ServiceNow's recent strategic partnerships and product integrations, such as with TechSee and Staffbase, underscore its commitment to enhancing enterprise workflows through its AI Platform. These collaborations not only expand ServiceNow's ecosystem but also integrate sophisticated AI tools directly into client operations, improving efficiency and user engagement. Notably, the company has also been proactive in share repurchases, buying back shares worth $360.96 million in Q2 2025 alone, reflecting confidence in its financial health and future prospects. Moreover, ServiceNow's innovative approach is evident in its agentic workforce management solutions that significantly automate IT operations and customer support processes—demonstrating a robust integration of AI across enterprise levels which is set to redefine productivity standards within the tech industry.

Click here and access our complete health analysis report to understand the dynamics of ServiceNow. Understand ServiceNow's track record by examining our Past report.NOW Revenue and Expenses Breakdown as at Aug 2025

Make It Happen

Click through to start exploring the rest of the 63 US High Growth Tech and AI Stocks now. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Searching for a Fresh Perspective?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PTGXPLTR and NOW.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments